July 2010
- SeneXtaAnnounces The Successful Completion of Phase I study with SNX-001
April 2010
- SeneXta to present at the Swiss Equity biotech day, April 13, 2010 -
Zurich
March 2010
- SeneXta was featured as "Emerging Company" on BioCentury March 1, 2010
- SeneXta to participate at the BIO-Europe Spring® 2010, March 8, 2010 Barcelona, Spain
January 2010
- SeneXta to present at the Biotech Showcase 2010 conference in San Francisco on January 12
December 2009
- SeneXta Announces Human Dosing with SNX-001 In Phase I
Study
October 2009
- SeneXta to present at the 2009 BIOCOM Investor Conference in San Diego on
October 27 www.biocom.org
September 2009
- SeneXta to present at Swiss-Scandinavian Bio Seminar in Zurich on October 1st
July 2009
- SeneXta Therapeutics SA
announces
FDA approval of Investigational New
May 2009
- “BioCentury select SENEXTA to present at Bioequity Europe 2009 as New Wave Company”
April 2009
- “CEO Enrico Braglia will present SeneXta at Lugano Communication Forum”
March 2009
- “Senexta successfully completed new IND Toxicology Package”
January 2009
- SeneXta signs Worldwide Exclusive License Agreement with University of Texas at El Paso
Download Senexta BrochureNovember 2008
- SeneXta starts preclinical development on SNX-001
- Prof. Fariello join SeneXta team as Clinical Advisor
- SeneXta completed cGMP development of SNX-001
- SeneXta signs letter of intent with University of Texas El Paso
- SeneXta Therapeutics SA is incorporated in Switzerland